Surgical Robotics Enters a Competitive Market for the First Time in Twenty Years

Robotic surgery spent two decades as effectively a single-platform category, with Intuitive's da Vinci systems installed in a large majority of hospitals performing robot-assisted procedures worldwide. That position was built on a real technical lead and reinforced by the ordinary dynamics of medical devices: surgeons train on one system, hospitals capitalize it over many years, and the switching cost is measured in retraining an entire surgical service. The expiry of foundational patents and the entry of large medical device manufacturers with their own platforms has, for the first time, produced a market where a hospital procuring a surgical robot has genuine alternatives to evaluate. The competitive pressure has landed hardest on the consumables model, which is where the economics of the category actually live. Surgical robot instruments are typically use-limited, expiring after a fixed number of procedures, so the recurring instrument and accessory spend over a system's life substantially exceeds its purchase price. Hospital finance departments have long understood this; what changed is the leverage to negotiate it. Competing platforms with different instrument pricing structures have made per-procedure consumable cost a live procurement variable rather than a fixed condition of participating in robotic surgery at all. The clinical evidence question remains the most contested part of the category and has not been resolved by competition. Robot-assisted approaches show clear advantages in specific procedures — prostatectomy being the most established — through reduced blood loss and shorter hospital stays. Across the broader range of general surgical procedures where robotic approaches have expanded, comparative evidence against conventional laparoscopy is more mixed, with several analyses finding longer operative times and higher costs without proportionate outcome differences. That distinction between procedures where the benefit is well demonstrated and those where the robot is mainly a different way of doing the same operation is where health system purchasers now concentrate their scrutiny. The segment moving fastest is not the large multi-arm platform but smaller, single-purpose systems: orthopaedic robots for joint replacement alignment, bronchoscopy platforms for peripheral lung nodule biopsy, and endoluminal systems. These have narrower clinical claims, lower capital costs, and clearer evidence for the specific thing they do, which makes the purchasing decision considerably easier to justify than a general-purpose platform bought on the expectation that surgical services will find uses for it. For hospitals outside major academic centres, that is increasingly the entry point into robotics.